
Cooper Companies (COO) Stock Forecast & Price Target
Cooper Companies (COO) Analyst Ratings
Bulls say
CooperCompanies demonstrated a robust financial performance with an operating margin of 27.0%, reflecting a year-over-year increase of 120 basis points and surpassing consensus expectations. The company's free cash flow is projected to reach $575-625 million in FY26, marking a significant year-over-year growth of 33-44%. Additionally, the strong demand for CooperSurgical's Paragard and the consistent growth in CooperVision highlight the potential for continued revenue and earnings growth, supporting a positive outlook for the company's stock.
Bears say
Cooper Companies faces a challenging outlook with projected organic revenue growth for FY26 decreasing slightly from 5.3% to 4.9% year-over-year, primarily due to intensified competition from e-commerce vendors and weaker sales in key markets, particularly China, where CVI experienced a notable 28% decline. The company's gross margin also faced pressure, decreasing by 80 basis points year-over-year to 66.2%, due to tariffs and an unfavorable product mix that fell short of consensus expectations. Additionally, the Fertility segment reported only 1% year-over-year sales growth, significantly below its historical growth trajectory, further indicating operational struggles amidst a competitive landscape and potential dis-synergies anticipated from separating its two business segments.
This aggregate rating is based on analysts' research of Cooper Companies and is not a guaranteed prediction by Public.com or investment advice.
Cooper Companies (COO) Analyst Forecast & Price Prediction
Start investing in Cooper Companies (COO)
Order type
Buy in
Order amount
Est. shares
0 shares